Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jcyt.2020.04.100 http://scihub22266oqcxt.onion/10.1016/j.jcyt.2020.04.100 32565132!7252029!32565132     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cytotherapy 2020 ; 22 (9): 474-481 Nephropedia Template TP {{tp|p=32565132|t=2020. Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies |pdf=|usr=}}{{32565132}} gab.com Text Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies JO: Cytotherapy http://www.kidney.de/pget.php?&tw=1&pmid=32565132 #FOAvip Coronavirus disease 2019 (SARS-CoV2) is an active global health threat for which treatments are desperately being sought. Even though most people infected experience mild to moderate respiratory symptoms and recover with supportive care, certain vulnerable hosts develop severe clinical deterioration. While several drugs are currently being investigated in clinical trials, there are currently no approved treatments or vaccines for COVID-19 and hence there is an unmet need to explore additional therapeutic options. At least three inflammatory disorders or syndromes associated with immune dysfunction have been described in the context of cellular therapy. Specifically, Cytokine Release Syndrome (CRS), Immune Reconstitution Inflammatory Syndrome (IRIS), and Secondary Hemophagocytic Lymphohistiocytosis (sHLH) all have clinical and laboratory characteristics in common with COVID19 and associated therapies that could be worth testing in the context of clinical trials. Here we discuss these diseases, their management, and potential applications of these treatment in the context of COVID-19. We also discuss current cellular therapies that are being evaluated for the treatment of COVID-19 and/or its associated symptoms. Twit Text FOAVip Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies ????Cytotherapy http://www.kidney.de/pget.php?&tw=1&pmid=32565132 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32565132 #FOAvip English Wikipedia <ref>{{Cite pmid|32565132}}</ref> Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies #MMPMID32565132 Cancio M; Ciccocioppo R; Rocco PRM; Levine BL; Bronte V; Bollard CM; Weiss D; Boelens JJ; Hanley PJ Cytotherapy 2020[Sep]; 22 (9): 474-481 PMID32565132show ga Coronavirus disease 2019 (SARS-CoV2) is an active global health threat for which treatments are desperately being sought. Even though most people infected experience mild to moderate respiratory symptoms and recover with supportive care, certain vulnerable hosts develop severe clinical deterioration. While several drugs are currently being investigated in clinical trials, there are currently no approved treatments or vaccines for COVID-19 and hence there is an unmet need to explore additional therapeutic options. At least three inflammatory disorders or syndromes associated with immune dysfunction have been described in the context of cellular therapy. Specifically, Cytokine Release Syndrome (CRS), Immune Reconstitution Inflammatory Syndrome (IRIS), and Secondary Hemophagocytic Lymphohistiocytosis (sHLH) all have clinical and laboratory characteristics in common with COVID19 and associated therapies that could be worth testing in the context of clinical trials. Here we discuss these diseases, their management, and potential applications of these treatment in the context of COVID-19. We also discuss current cellular therapies that are being evaluated for the treatment of COVID-19 and/or its associated symptoms. |Adrenal Cortex Hormones/therapeutic use[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/drug therapy/*etiology/physiopathology[MESH] |Cytokine Release Syndrome/etiology/therapy[MESH] |Humans[MESH] |Immune Reconstitution Inflammatory Syndrome/etiology/therapy[MESH] |Immunization, Passive[MESH] |Interleukin-1/antagonists & inhibitors[MESH] |Interleukin-6/antagonists & inhibitors[MESH] |Killer Cells, Natural/immunology[MESH] |Lymphohistiocytosis, Hemophagocytic/etiology/therapy[MESH] |Pandemics[MESH] |Plasmapheresis[MESH] |Pneumonia, Viral/*etiology/physiopathology[MESH]Emerging trends in COVID-19 treatment: learning from inflammatory cond(epmc).pdf DeepDyve Pubget Overpricing